Topics

Glioblastoma | Treatment | Immunotherapy | Immune Checkpoint Inhibitors

Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Immune Checkpoint Inhibitors

Wang H, Yang J, Li X, Zhao H.
Current state of immune checkpoints therapy for glioblastoma.
Heliyon. 2024 Jan 13;10(2):e24729. doi: 10.1016/j.heliyon.2024.e24729. PMID: 38298707. Review. ˍ

Ser MH, Webb MJ, Sener U, Campian JL.
Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions.
J Immunother Precis Oncol. 2024 May 2;7(2):97-110. doi: 10.36401/JIPO-23-34. PMID: 38721406. Review. ˍ

Wu J, Wang N.
Current progress of anti-PD-1/PDL1 immunotherapy for glioblastoma (Review).
Mol Med Rep. 2024 Sep 30;30(6):221. doi: 10.3892/mmr.2024.13344. PMID: 39364736. Review. ˍ

Rodriguez SMB, Tataranu LG, Kamel A, Turliuc S, Rizea RE, Dricu A.
Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions.
Int J Mol Sci. 2024 Oct 7;25(19):10765. doi: 10.3390/ijms251910765. PMID: 39409094. Review. ˍ

Du R, Zhang J, Lukas RV, Tripathi S, Ahrendsen JT, Curran MA, Dmello C, Zhang P, Stupp R, Rao G, Heimberger AB.
Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?
Neuro Oncol. 2024 Oct 19:noae193. doi: 10.1093/neuonc/noae193. PMID: 39427326. Review. ˍ

Schonfeld E, Choi J, Tran A, Kim LH, Lim M.
The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review.
Neurooncol Adv. 2024 Nov 12;6(1):vdae174. doi: 10.1093/noajnl/vdae174. PMID: 39534539. Review. ˍ

Badani A, Ozair A, Khasraw M, Woodworth GF, Tiwari P, Ahluwalia MS, Mansouri A.
Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions.
J Neurooncol. 2024 Nov 21. doi: 10.1007/s11060-024-04881-2. PMID: 39570554. Review˰ ˍ

Baskaran AB, Kozel OA, Venkatesh O, Wainwright DA, Sonabend AM, Heimberger AB, Lukas RV.
Immune Checkpoint Inhibitors in Glioblastoma IDHwt Treatment: A Systematic Review.
Cancers (Basel). 2024 Dec 12;16(24):4148. doi: 10.3390/cancers16244148. PMID: 39766048. Review. ˍ

de Melo SM, Elias Nunes da Silva ME, Torloni MR, Riera R, De Cicco K, Latorraca CO, Pinto ACPN.
Anti-PD-1 and anti-PD-L1 antibodies for glioma.
Cochrane Database Syst Rev. 2025 Jan 8;1(1):CD012532. doi: 10.1002/14651858.CD012532.pub2. PMID: 39777725. Meta-analysis˰ ˍ

Murugan AK, Kannan S, Alzahrani AS.
Immune checkpoint expression and therapeutic implications in IDH1-mutant and wild-type glioblastomas.
Curr Probl Cancer. 2025 Jan 25;55:101182. doi: 10.1016/j.currproblcancer.2025.101182. PMID: 39864140. Laboratory investigation˰ ˍ

Zoi V, Galani V, Sioka C, Alexiou GA, Kyritsis AP.
Immunotherapy for Glioblastoma: A Focus on PD-1/PD-L1 Inhibitors.
Cancers (Basel). 2025 Nov 26;17(23):3777. doi: 10.3390/cancers17233777. PMID: 41374979. Review. ˍ